SERA (Sera Prognostics) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SERA Sera Prognostics Inc SERA
69 GF Score
Price $2.05
GF Value $1.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sera Prognostics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

SERA
69GF Score
Sera Prognostics Inc SERA
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sera Prognostics (SERA) Overvalued in 2026?

Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued. The current stock price of $2.05 is trading 12% above its estimated GF Value™ of $1.83. GuruFocus considers Sera Prognostics to be Modestly Overvalued.

Key valuation signals for SERA:

  • Short Ratio:
  • GF Value™: $1.83 vs. price of $2.05 (12% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sera Prognostics Business Description

Address 2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
69GF Score

Get the complete analysis for SERA

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05
Price
$1.83
GF Value